Best in Class Case Study- Big Data & Cancer Research

By:
Posted: 06/24/2015

  As of now, big data is not utilised as often and as well as it could be in the Pharmaceutical Industry.Data usage could lead to accelerated drug discovery and better help patients, enabling companies to streamline, become more productive, more efficient, and reduce costs. Allan Jordan strongly believes that while big data is important and can change Pharma, it should not just be gathered without reason. There needs to be a purpose, and purpose is the main thing driving his latest project.

The project in question is focused on exploiting genome sequencing efforts to discover new targets for cancer treatment. Allan and his team are working to combine unexploited genomic data with a new concept called collateral vulnerability to try and find weaknesses within tumour cells. This is a huge opportunity for positive change. The goal is finding treatments for cancer patients who haven’t had ideal responses to chemotherapy
 
Have Your Say
Rate this feature and give us your feedback in the comments section below
To continue viewing this content please fill out the form below and become an Pharma IQ member.
Or if you're already a Pharma IQ member, sign in below to download.
Join

By entering in your information and submitting the form, you give the sponsor permission to contact you regarding their product and you agree to our User Agreement, Privacy Policy, and Cookie Policy.

By:
Posted: 06/24/2015

Pharma IQ Members